1. Home
  2. BENF vs WINT Comparison

BENF vs WINT Comparison

Compare BENF & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BENF
  • WINT
  • Stock Information
  • Founded
  • BENF 2003
  • WINT 1992
  • Country
  • BENF United States
  • WINT United States
  • Employees
  • BENF N/A
  • WINT N/A
  • Industry
  • BENF Blank Checks
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BENF Finance
  • WINT Health Care
  • Exchange
  • BENF Nasdaq
  • WINT Nasdaq
  • Market Cap
  • BENF 2.6M
  • WINT 2.2M
  • IPO Year
  • BENF N/A
  • WINT 1995
  • Fundamental
  • Price
  • BENF $0.29
  • WINT $0.93
  • Analyst Decision
  • BENF
  • WINT Hold
  • Analyst Count
  • BENF 0
  • WINT 1
  • Target Price
  • BENF N/A
  • WINT $350.00
  • AVG Volume (30 Days)
  • BENF 196.7K
  • WINT 15.2M
  • Earning Date
  • BENF 08-13-2025
  • WINT 08-18-2025
  • Dividend Yield
  • BENF N/A
  • WINT N/A
  • EPS Growth
  • BENF N/A
  • WINT N/A
  • EPS
  • BENF N/A
  • WINT N/A
  • Revenue
  • BENF N/A
  • WINT N/A
  • Revenue This Year
  • BENF N/A
  • WINT N/A
  • Revenue Next Year
  • BENF N/A
  • WINT N/A
  • P/E Ratio
  • BENF N/A
  • WINT N/A
  • Revenue Growth
  • BENF N/A
  • WINT N/A
  • 52 Week Low
  • BENF $0.22
  • WINT $0.36
  • 52 Week High
  • BENF $6.27
  • WINT $737.44
  • Technical
  • Relative Strength Index (RSI)
  • BENF 45.00
  • WINT 64.37
  • Support Level
  • BENF $0.28
  • WINT $0.52
  • Resistance Level
  • BENF $0.32
  • WINT $0.49
  • Average True Range (ATR)
  • BENF 0.02
  • WINT 0.10
  • MACD
  • BENF 0.00
  • WINT 0.06
  • Stochastic Oscillator
  • BENF 45.27
  • WINT 86.24

About BENF Beneficient

Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and an innovative financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Share on Social Networks: